JTZ 951

Drug Profile

JTZ 951

Alternative Names: JTZ-951

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Japan Tobacco
  • Class Antianaemics
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 18 Jan 2017 Japan Tobacco completes a phase II trial for Anaemia (In patients with chronic kidney disease not requiring dialysis) (PO) (JapicCTI-152881)
  • 18 Jan 2017 Japan Tobacco completes two phase II trials for Anaemia (In patients with chronic kidney disease receiving maintenance haemodialysis) in Japan (PO) (JapicCTI152891; JapicCTI152892)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top